Bausch + Lomb Corporation (NYSE:BLCO) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Robbie Marcus - JPMorgan Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Matt Miksic - Barclays Doug Miehm - RBC Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2024 Earnings Call. [Opera ...

Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP) to GAAP net income (loss) attributable to Bausch + Lomb Corporation or of forward-looking constant currency revenue growth to reported revenue growth, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, cou ...

Bausch + Lomb (BLCO) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnin ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”). With Ms. Ling’s appointment, the Board has been temporarily expanded t ...

Bausch + Lomb Corporation (NYSE:BLCO) Q4 2023 Earnings Conference Call February 21, 2024 8:00 AM ET Company Participants Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO George Gadkowski - VP, IR & Business Insights Conference Call Participants Matt Miksic - Barclays Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - J.P. Morgan Vijay Kumar - Evercore ISI Joanne Wuensch - Citibank Operator Good morning, and welcome to the Bausch + Lomb’s Fourt ...

Bausch + Lomb (BLCO) reported $1.17 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of $0.24 for the same period compares to $0.23 a year ago.The reported revenue represents a surprise of +7.50% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.17, the EPS surprise was +41.18%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

Bausch + Lomb Corp.’s stock soared 10% early Wednesday, after the vision-care company’s adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024. The Vaughan, Ontario-based company BLCO, +1.96% had a net loss of $54 million, or 15 cents a share, for the quarter, after a loss of $1 million in the year-earlier period. Adjusted per-share earnings came to 24 cents, ahead of the 17-cent FactSet consensus.Revenue rose to $1.173 billion from $996 million a year ago, also ahe ...

9 1. Products with sales outside the United States impacted by F/X changes. 2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios. 3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the repo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) ...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance VAUGHAN, Ontario, Feb. 21, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full year 2023 financial results. Select Fourth-Quarter Company Highlights ___________________________________ 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and n ...